Cite
MLA Citation
Bruria Hirsh Raccah et al.. “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.” International journal of cardiology, vol. 335, 2021, pp. 7–14. http://access.bl.uk/ark:/81055/vdc_100132604796.0x000047